Chapter 1. Introduction1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive SummaryChapter 4. Market Outlook4.1. Market Dynamics
4.1.1. Market Drivers
4.1.2. Market Restraints
4.1.3. Market Opportunities
4.2. Porter’s Analysis
4.3. Value Chain Analysis
Chapter 5. Hypoxia Market, By Type5.1. Hypoxia Market, By Type, 2018-2026
5.2. BC-001
5.3. CASI-2ME2
5.4. CRLX-101
5.6. Others
Chapter 6. Hypoxia Market, By Application6.1. Hypoxia Market, by Application, 2018-2026
6.2. Solid Tumor
6.3. Acute Myelocytic Leukemia
6.4. Colorectal Cancer
6.5. Others
Chapter 7. Hypoxia Market, By Region7.1. Hypoxia Market, by Region, 2018-2026
7.1.1. North America
7.1.1.1. U.S
7.1.1.2. Rest of North America
7.1.2. Europe
7.1.2.1. U.K.
7.1.2.2. Germany
7.1.2.3. France
7.1.2.4. Rest of the Europe
7.1.3. Middle East & Africa (MEA)
7.1.3.1. GCC
7.1.3.2. North Africa
7.1.3.3. South Africa
7.1.3.4. Rest of MEA
7.1.4. Latin America (LATAM)
7.1.4.1. Brazil
7.1.4.2. Rest of LATAM
7.1.5. Asia Pacific (APAC)
7.1.5.1. India
7.1.5.2. China
7.1.5.3. Japan
7.1.5.4. Rest of the APAC
Chapter 8. Competitive Landscape8.1.1. Key Strategies Adopted by Players
8.1.2. Market Share/Positioning Analysis
Chapter 9. Company Profiles9.1. Aileron Therapeutics, Inc.
9.1.1. Company Overview
9.1.2. Product Offerings
9.1.3. Financial Performance
9.1.4. Recent Initiatives
9.2. CASI Pharmaceuticals Inc.
9.2.1. Company Overview
9.2.2. Product Offerings
9.2.3. Financial Performance
9.2.4. Recent Initiatives
9.3. Cerulean Pharma, Inc.
9.3.1. Company Overview
9.3.2. Product Offerings
9.3.3. Financial Performance
9.3.4. Recent Initiatives
9.4. F. Hoffmann-La Roche Ltd.
9.4.1. Company Overview
9.4.2. Product Offerings
9.4.3. Financial Performance
9.4.4. Recent Initiatives
9.5 InterMed Discovery GmbH
9.5.1. Company Overview
9.5.2. Product Offerings
9.5.3. Financial Performance
9.5.4. Recent Initiatives
9.6. OncoImmune, Inc.
9.6.1. Company Overview
9.6.2. Product Offerings
9.6.3. Financial Performance
9.6.4. Recent Initiatives
9.7. Peloton Therapeutics, Inc.
9.7.1. Company Overview
9.7.2. Product Offerings
9.7.3. Financial Performance
9.7.4. Recent Initiatives
9.8. RXi Pharmaceuticals Corporation
9.8.1. Company Overview
9.8.2. Product Offerings
9.8.3. Financial Performance
9.8.4. Recent Initiatives
9.9. Sorrento Therapeutics, Inc.
9.9.1. Company Overview
9.9.2. Product Offerings
9.9.3. Financial Performance
9.9.4. Recent Initiatives
9.10. Transcriptogen Ltd
9.10.1. Company Overview
9.10.2. Product Offerings
9.10.3. Financial Performance
9.10.4. Recent Initiatives
9.11. Vascular Biogenics Ltd.
9.11.1. Company Overview
9.11.2. Product Offerings
9.11.3. Financial Performance
9.11.4. Recent Initiatives
9.12. List of other companies
9.12.1. Company Overview
9.12.2. Product Offerings
9.12.3. Financial Performance
9.12.4. Recent Initiatives
Chapter 10. Appendix10.1. About Us
10.2. Glossary of Terms